The groundbreaking success of Sildenafil undeniably reshaped the drug landscape, but betting in companies primarily reliant on unbranded versions presents a uncertain picture. While early profits were significant, the end of patents and the rise of less expensive alternatives have weakened the customer base. Therefore, a thorough analysis of curren